As indicated by studies demonstrating benefit with the missing KIR ligand, anti-GD2 therapy could induce ADCC more effectively with KIR mismatch in which NK cells are not inhibited by the presence of self-HLA on target tumor, which could be accomplished with infusion of allogeneic NK cells that are KIR mismatched from the recipient. Here, KIR3DL1 is linked to neoplasm.